Related Experiment Video

Updated: Nov 15, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.9K

Targeting the epigenome in in-stent restenosis: from mechanisms to therapy

Xi Yang1, Yanyan Yang2, Junjie Guo1

  • 1Department of Cardiology, The Affiliated Hospital of Qingdao University, Road No. 59 Haier, Qingdao 266100, Shandong, People's Republic of China.

Molecular Therapy. Nucleic Acids
|March 5, 2021
PubMed

Insights

Epigenetics, including DNA methylation, histone modification, and non-coding RNAs, plays a key role in in-stent restenosis (ISR) after coronary artery disease treatment. Understanding these epigenetic mechanisms offers new therapeutic targets for improving ISR treatment.

Area of Science:

  • Cardiovascular Biology
  • Epigenetics
  • Interventional Cardiology

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality globally.
  • Percutaneous coronary intervention (PCI) with stenting is a primary treatment for CAD.
  • In-stent restenosis (ISR), lumen re-narrowing post-PCI, remains a significant clinical challenge, driven by vascular smooth muscle cell proliferation and endothelial cell dysfunction.

Purpose of the Study:

  • To provide a comprehensive analysis of epigenetic mechanisms regulating ISR.
  • To elucidate the role of DNA methylation, histone modification, and non-coding RNAs in ISR.
  • To explore potential therapeutic strategies targeting epigenetic factors in ISR.

Main Methods:

  • Review of current literature on epigenetics and ISR.
  • Analysis of molecular mechanisms underlying epigenetic regulation in vascular cells.
  • Discussion of small molecule inhibitors for cardiovascular epigenetic factors.

Main Results:

  • Epigenetic modifications are increasingly recognized as critical regulators of ISR.
  • Aberrant gene expression and cellular functions in VSMCs and ECs are modulated by epigenetic changes.
  • Specific epigenetic pathways offer promising targets for novel ISR therapies.

Conclusions:

  • Epigenetic mechanisms are central to the pathogenesis of ISR.
  • Targeting epigenetic factors presents a promising avenue for developing improved therapies for ISR.
  • Further research into cardiovascular epigenetics is essential for advancing ISR treatment.

Keywords:
DNA methylationepigeneticshistone modificationin-stent restenosisnon-coding RNAstarget therapy

More Related Videos

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

1.6K
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
111
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.4K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
110